- Oops!Something went wrong.Please try again later.
Next generation Tau PET-Tracer, 18F-PI-2620, offers opportunities to diagnose and monitor tauopathies, including AD and PSP
New data further support 18F-PI-2620’s potential as a new PET Tracer for progressive supranuclear palsy (PSP) detection
LAUSANNE, Switzerland, March 27, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Life Molecular Imaging (LMI, formerly Piramal Imaging) together with its collaboration partners will present new data on 18F-PI-2620, a novel next generation investigational Tau PET-tracer, at the 14th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM), taking place March 26th-31st in Lisbon.
The progression of Tau pathology has been shown to be closely associated with neuronal loss, neurodegeneration, and cognitive decline in Alzheimer’s disease and other tauopathies. AC Immune discovered investigational Tau PET tracers using its MorphomerTM small molecule discovery platform.
LMI is developing 18F-PI-2620 for detection of the two isoforms of Tau aggregates in AD and Non-AD Tauopathies that are characterized by different Tau isoforms (3R and 4R) 18F-PI-2620 has potential applications as a diagnostic agent to confirm and monitor disease progression as well as responses to treatment. Due to its excellent signal-to-background ratio, 18F-PI-2620 has the potential to detect Tau deposits in early stages of AD. To date, no Tau tracer has been approved by the Food and Drug Administration for use in the evaluation of AD or other tauopathies.
“We are particularly pleased that 18F-PI-2620 depicts the characteristic Tau-deposition pattern in patients with Progressive Supranuclear Palsy (PSP)” said Prof. Andrea Pfeifer, Ph.D., CEO of AC Immune. “18F-PI-2620’s unique feature of low off-target binding and detection of 4R tauopathies, such as PSP, allow us to pursue precision medicine, enabling more effective development of therapeutics for patients suffering from this life-threatening NeuroOrphan disease, for which there is no treatment or cure.”
The following presentations on 18F-PI-2620 will be provided at the AD/PD conference by scientists from Life Molecular Imaging and its collaboration partners:
Determination of the optimal scanning time for the assessment of Tau deposition in Alzheimer’s Disease using PI-2620 PET
Date: March 29, 2019 | 10.30 – 10.45 am WET
Location: Auditorium III+IV
Presenter: Oral presentation by A. Stephens
18F-PI-2620 Tau-PET in progressive supranuclear palsy – a multi-center evaluation
Date: March 31 | 14.00 – 14.15 pm WET
Location: Auditorium VI+VII
Presenter: Oral presentation by T. Van Eimeren
Evaluation of Tau deposition in amyloid positive MCI or mild-AD dementia subjects from the elenbecestat MissionAD program using 18F-PI-2620 PET
Date: March 27-28 | 6.00 – 16.00 pm WET
Presenter: Poster presentation by A. Stephens
Under the 2014 agreement LMI has exclusive global rights for clinical development, manufacturing and commercialization of Tau-PET tracers resulting from the joint discovery and development collaboration. In exchange, AC Immune is eligible for milestone payments on development milestones and tiered royalties on sales.
About AC Immune
AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neuro-degenerative diseases. The Company is utilizing two proprietary discovery platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Lilly and Janssen.
For further information, please contact:
European Investors & Media
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.